Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time

Choay, 1983, Structure–activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti‐factor Xa activity, Biochem Biophys Res Commun, 116, 492, 10.1016/0006-291X(83)90550-8 Petitou, 1999, Synthesis of thrombin‐inhibiting heparin mimetics without side effects, Nature, 398, 417, 10.1038/18877 Benchekroun, 1986, Heparin half‐life and sensitivity in normal subjects and in patients affected by deep vein thrombosis, Eur J Clin Invest, 16, 536, 10.1111/j.1365-2362.1986.tb02174.x Levine, 1984, The effect of platelet factor 4 (PF4) on assays of plasma heparin, Br J Haematol, 57, 585, 10.1111/j.1365-2141.1984.tb02936.x Young, 1992, Heparin binding to plasma proteins, an important mechanism for heparin resistance, Thromb Haemost, 67, 639, 10.1055/s-0038-1648515 Sephton, 2003, A longitudinal study of maternal dose–response to low molecular weight heparin in pregnancy, Obstet Gynecol, 101, 1307 Vermylen, 1987, Decreased sensitivity to heparin in vitro in steroid‐responsive nephrotic syndrome, Kidney Int, 31, 1396, 10.1038/ki.1987.155 White, 1997, Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady‐state intravenous heparin requirements, Arch Intern Med, 157, 2468, 10.1001/archinte.1997.00440420100009 Vieira, 1991, Heparin sensitivity and resistance in the neonate: an explanation, Thromb Res, 63, 85, 10.1016/0049-3848(91)90272-X D'Errico, 1996, Age‐related differences in heparin sensitivity and heparin–protamine interactions in cardiac surgery patients, J Cardiothorac Vasc Anesth, 10, 451, 10.1016/S1053-0770(05)80003-5 Hainer, 2002, Dosing in heavy‐weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study, Thromb Haemost, 87, 817, 10.1055/s-0037-1613090 Legnani, 2002, Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited, Haematologica, 87, 182 Kitchen, 1996, Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage, J Clin Pathol, 49, 10, 10.1136/jcp.49.1.10 Bjornsson, 1986, Variability in heparin sensitivity of APTT reagents, Am J Clin Pathol, 86, 199, 10.1093/ajcp/86.2.199 Greaves, 2002, Thromb Haemost, 87, 163, 10.1055/s-0037-1612960 Van Den Besselaar, 1995, Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometers, Thromb Haemost, 74, 1383, 10.1055/s-0038-1649948 Smythe, 2001, Use of the activated partial thromboplastin time for heparin monitoring, Am J Clin Pathol, 115, 148, 10.1309/N7RA-D6XN-9EQX-ABJ9 Van Den Besselaar, 1989, Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: where should we go?, Ric Clin Lab, 19, 371, 10.1007/BF02871828 Toulon, 1998, Monitoring heparin therapy using activated partial thromboplastin time—results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin, Thromb Haemost, 80, 104, 10.1055/s-0037-1615147 Manzato, 1998, Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring, Clin Chem Lab Med, 36, 975, 10.1515/CCLM.1998.168 Baker, 1997, Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays, Arch Intern Med, 157, 2475, 10.1001/archinte.1997.00440420107010 Van Den Besselaar, 1997, Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy, Clin Chem, 43, 1215, 10.1093/clinchem/43.7.1215 Murray, 1999, Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding, Transfusion, 39, 56, 10.1046/j.1537-2995.1999.39199116895.x Kher, 1997, Laboratory assessment of antithrombotic therapy: what tests and if so why?, Haemostasis, 27, 211 Hirsh, 2001, Heparin and low‐molecular‐weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest, 119, 64S, 10.1378/chest.119.1_suppl.64S Frederiksen, 2003, Enoxaparin effect depends on body‐weight and current doses may be inadequate in obese patients, Br J Surg, 90, 547, 10.1002/bjs.4068 Alban, 2002, Pharmacokinetic and pharmacodynamic characterization of a medium‐molecular‐weight heparin in comparison with UFH and LMWH, Semin Thromb Hemost, 28, 369, 10.1055/s-2002-34306 Abilgaard, 1976, A simple amidolytic method for the determination of functional active antithrombin III, Scand J Clin Lab Invest, 36, 109, 10.1080/00365517609068026 Odegard, 1976, Antifactor Xa activity measured with amidolytic methods, Haemostasis, 5, 265 Wielders, 1997, The routine determination of the endogenous thrombin potential, first results in different forms of hyper‐ and hypocoagulability, Thromb Haemost, 77, 629, 10.1055/s-0038-1656024 Beguin, 1988, The mode of action of heparin in plasma, Thromb Haemost, 60, 457, 10.1055/s-0038-1646990 Hemker, 1986, A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes, Thromb Haemost, 56, 9, 10.1055/s-0038-1661594 Duchemin, 1994, A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma, Thromb Haemost, 71, 331, 10.1055/s-0038-1642439 Hemker, 2003, Calibrated automated thrombin generation measurement in clotting plasma, Pathophysiol Haemost Thromb, 33, 4, 10.1159/000071636 Al Dieri, 2003, The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif—the C‐domain, J Thromb Haemost, 1, 907, 10.1046/j.1538-7836.2003.00211.x Gouin‐Thibault, 2003, In vitro interaction of the pentasaccharide idraparinux (SanOrg 34006) with unfractionated heparin, J Thromb Haemost, 1, 2054, 10.1046/j.1538-7836.2003.00384.x Ip, 2001, A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low‐molecular weight heparin, Pathology, 33, 347, 10.1080/00313020126304 Alhenc‐Gelas, 1994, Adjusted versus fixed doses of the low‐molecular‐weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin‐Study Group, Thromb Haemost, 71, 698, 10.1055/s-0038-1642507